The fact remains that the Phylomer "platform" is vastly broader than simply a screening base for endosome penetration peptides.
While the technology is hugely valuable, if PYC can arrange a commercial deal, it would be best to "spin off" this technology in a separate business unit and continuing on to apply the Phylomer technologies to other (diverse) problems.
PYC has a number of "short game" options:
- Immunology
- Cell Apotosis
- Endosomal Escape Trap
There are also a large number of "long game" opportunities.
This "snowball" could roll down hill for a very long time (to reference WB).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.040(3.03%) |
Mkt cap ! $746.5M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.35 | $1.28 | $764.7K | 579.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4000 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 40248 | 3 |
View Market Depth
| Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |